spacer
home > ict > autumn 2017 > restricting regulations
PUBLICATIONS
International Clinical Trials

Restricting Regulations

Contemporary medicine has come a long way since the days of snake oil salesmen. Today, patients can be assured that prescribed medicine has been vetted for safety and efficacy through a long and arduous process, guided by governmental regulatory agencies. The central pillar of this rigorous procedure for current drug approval is the human clinical trial, the success of which has resulted in a proliferation of studies worldwide. Since the international committee of medical journal editors established trial registration requirements in 2005, enrolment has increased fivefold (1). In the US alone, clinical trial registration has increased tenfold during this same time period, but, against this backdrop, the EU recorded a concerning 25% decrease in clinical trial applications (CTA) from 2007 to 2011 (2).

Global Trials

One of the issues affecting the number of EU studies is a growing trend towards globalisation, with a recent rise in those conducted in developing countries. For example, the number of countries serving as study locations outside the US has more than doubled in the past 10 years, and the proportion of trials undertaken there and in Western Europe has reduced significantly (3,4).

Several factors drive this globalisation trend – one of them being the spiralling drug development costs. A 2013 study by the Tufts Center for the Study of Drug Development estimates the average expense to develop and gain market approval for a new therapeutic is $2.6 billion – up 145% from a similar investigation conducted in 2003 – with time costs accounting for half of that amount. The time and investment required to conduct trials is the largest contributor to these increases, and, given that the success rate for medications moving through clinical trials to FDA approval is a mere 10%, the pharmaceutical industry is struggling to sustain profitability (5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Craig Morgan is Head of Marketing at goBalto, a life sciences software as a service technology organisation. He works with sponsors, CROs, medical device manufacturers and sites to reduce cycle times and improve collaboration and oversight in clinical trials. Craig is a technology and life sciences management professional, with over 15 years’ experience in informatics and bioinformatics applications to drug discovery. He holds degrees in analytical chemistry, information systems and business administration and is a certified
spacer
Craig Morgan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Innovative Micro-Infusion Pump for Gerresheimer Subsidiary Sensile Medical Developed and Successfully Launched for EVER Pharma

Düsseldorf/Olten, July 03, 2019 – Developed specially by Sensile Medical for EVER Pharma under the brand name D-mine®, this wearable microinfusion pump recently received European CE certification and has already been launched in several European countries. The compact, patient-friendly infusion pump is used for the continuous subcutaneous administration of drugs to treat Parkinson’s disease. The first micro pump from Gerresheimer subsidiary Sensile Medical to be available on the market, it gives Parkinson’s patients greater independence in their day-today lives.
More info >>

White Papers

What Your Clinical Study Design Reveals About Your Clinical Packaging Needs

PCI Pharma Services

As the cost and complexities of drug development increase, so do the challenges of global clinical trials. Today’s sponsors must be able to manage and coordinate multiple resources, processes, and locations with speed and accuracy to design effective and efficient clinical trials. Securing a stable supply chain to deal with the uncertainties of clinical trials is critical. One misstep can have a profound impact not only on the cost and time of your trial but also on its overall success.
More info >>

 
Industry Events

Clinical Trials Europe | Partnerships, Outsourcing, Operations & Technology

27 August - 21 November 2019, Barcelona, Spain

On 19-21 November 2019, the clinical trial community's most influential stakeholders will be meeting in Barcelona to discuss the evolving landscape, honing in on what it takes to harness true value from partnerships, outsourcing, operations, technology and early clinical development, for a faster, more efficient route to market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement